These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
684 related items for PubMed ID: 29576307
21. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Hum Vaccin Immunother; 2012 Dec 01; 8(12):1892-903. PubMed ID: 23032159 [Abstract] [Full Text] [Related]
22. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children. Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C. Vaccine; 2020 May 08; 38(22):3902-3908. PubMed ID: 32284274 [Abstract] [Full Text] [Related]
23. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C. Pediatr Infect Dis J; 2012 Jan 08; 31(1):e15-23. PubMed ID: 22094636 [Abstract] [Full Text] [Related]
24. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Ilyina N, Kharit S, Namazova-Baranova L, Asatryan A, Benashvili M, Tkhostova E, Bhusal C, Arora AK. Hum Vaccin Immunother; 2014 Jan 08; 10(8):2471-81. PubMed ID: 25424958 [Abstract] [Full Text] [Related]
25. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J. Eur J Pediatr; 2013 May 08; 172(5):601-12. PubMed ID: 23307281 [Abstract] [Full Text] [Related]
28. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. BMC Infect Dis; 2013 Mar 05; 13():116. PubMed ID: 23510357 [Abstract] [Full Text] [Related]
29. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I. Vaccine; 2015 May 15; 33(21):2500-10. PubMed ID: 25795256 [Abstract] [Full Text] [Related]
33. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study. Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E, Dhingra MS. Pediatr Infect Dis J; 2020 Oct 15; 39(10):955-960. PubMed ID: 32852352 [Abstract] [Full Text] [Related]
34. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial. Knuf M, Rämet M, Breinholt Stærke N, Bertrand-Gerentes I, Thollot Y, B'Chir S, Arroum H, Oster P. Hum Vaccin Immunother; 2022 Nov 30; 18(5):2052657. PubMed ID: 35445641 [Abstract] [Full Text] [Related]
35. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group. Pediatr Infect Dis J; 2010 Jan 30; 29(1):48-52. PubMed ID: 20035207 [Abstract] [Full Text] [Related]
36. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy. Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P, Rinderknecht S, Blatter M, Bianco V, Baine Y, Friedland LR, Miller JM. Vaccine; 2015 Feb 11; 33(7):933-41. PubMed ID: 25152325 [Abstract] [Full Text] [Related]
39. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. BMC Infect Dis; 2020 Jun 18; 20(1):426. PubMed ID: 32552685 [Abstract] [Full Text] [Related]
40. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine. Quiambao B, Peyrani P, Li P, Cutler MW, Van Der Wielen M, Perez JL, Webber C. Hum Vaccin Immunother; 2020 Jun 02; 16(6):1272-1279. PubMed ID: 32401600 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]